GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shockwave Medical Inc (NAS:SWAV) » Definitions » Beneish M-Score

Shockwave Medical (Shockwave Medical) Beneish M-Score : -2.89 (As of May. 06, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shockwave Medical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.89 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Shockwave Medical's Beneish M-Score or its related term are showing as below:

SWAV' s Beneish M-Score Range Over the Past 10 Years
Min: -2.89   Med: -0.76   Max: 1.75
Current: -2.89

During the past 7 years, the highest Beneish M-Score of Shockwave Medical was 1.75. The lowest was -2.89. And the median was -0.76.


Shockwave Medical Beneish M-Score Historical Data

The historical data trend for Shockwave Medical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shockwave Medical Beneish M-Score Chart

Shockwave Medical Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial -0.76 -1.85 0.25 1.75 -2.89

Shockwave Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.75 0.95 5.74 1.28 -2.89

Competitive Comparison of Shockwave Medical's Beneish M-Score

For the Medical Devices subindustry, Shockwave Medical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shockwave Medical's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shockwave Medical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Shockwave Medical's Beneish M-Score falls into.



Shockwave Medical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Shockwave Medical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0765+0.528 * 0.9976+0.404 * 0.9414+0.892 * 1.4911+0.115 * 0.5985
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0112+4.679 * -0.045238-0.327 * 2.933
=-2.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $114.6 Mil.
Revenue was 202.979 + 186.02 + 180.165 + 161.066 = $730.2 Mil.
Gross Profit was 177.663 + 161.507 + 155.672 + 140 = $634.8 Mil.
Total Current Assets was $1,225.3 Mil.
Total Assets was $1,566.6 Mil.
Property, Plant and Equipment(Net PPE) was $98.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $10.4 Mil.
Selling, General, & Admin. Expense(SGA) was $330.1 Mil.
Total Current Liabilities was $104.2 Mil.
Long-Term Debt & Capital Lease Obligation was $767.0 Mil.
Net Income was 44.305 + 34.986 + 28.862 + 39.125 = $147.3 Mil.
Non Operating Income was 15.128 + 3.966 + 1.44 + 1.559 = $22.1 Mil.
Cash Flow from Operations was 71.703 + 50.651 + 39.737 + 33.962 = $196.1 Mil.
Total Receivables was $71.4 Mil.
Revenue was 144.026 + 131.33 + 120.746 + 93.631 = $489.7 Mil.
Gross Profit was 126.524 + 113.456 + 104.016 + 80.741 = $424.7 Mil.
Total Current Assets was $459.3 Mil.
Total Assets was $646.1 Mil.
Property, Plant and Equipment(Net PPE) was $80.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.9 Mil.
Selling, General, & Admin. Expense(SGA) was $218.9 Mil.
Total Current Liabilities was $63.4 Mil.
Long-Term Debt & Capital Lease Obligation was $59.1 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(114.552 / 730.23) / (71.366 / 489.733)
=0.156871 / 0.145724
=1.0765

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(424.737 / 489.733) / (634.842 / 730.23)
=0.867283 / 0.869373
=0.9976

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1225.26 + 98.63) / 1566.563) / (1 - (459.263 + 80.517) / 646.089)
=0.154908 / 0.164542
=0.9414

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=730.23 / 489.733
=1.4911

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(4.856 / (4.856 + 80.517)) / (10.358 / (10.358 + 98.63))
=0.05688 / 0.095038
=0.5985

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(330.102 / 730.23) / (218.924 / 489.733)
=0.452052 / 0.447027
=1.0112

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((766.966 + 104.205) / 1566.563) / ((59.126 + 63.374) / 646.089)
=0.556103 / 0.189602
=2.933

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(147.278 - 22.093 - 196.053) / 1566.563
=-0.045238

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Shockwave Medical has a M-score of -2.89 suggests that the company is unlikely to be a manipulator.


Shockwave Medical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Shockwave Medical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shockwave Medical (Shockwave Medical) Business Description

Traded in Other Exchanges
Address
5403 Betsy Ross Drive, Santa Clara, CA, USA, 95054
ShockWave Medical Inc is a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Its intravascular lithotripsy technology is used in the treatment of calcified plaque. Geographically, the company generates its revenue from the United States, Europe and other countries.
Executives
Douglas Evan Godshall director, officer: President & CEO SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Frank T Watkins director 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Isaac Zacharias officer: Chief Commercial Officer 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Dan Puckett officer: CFO & Secretary 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Trinh Phung officer: VP, Finance C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Laura Francis director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Sara Toyloy director C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Kevin J. Ballinger director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Antoine Papiernik director, 10 percent owner 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Sofinnova Capital Vii Fcpr 10 percent owner C/O SOFINNOVA PARTNERS, 18 RUE DU 4 SEPTEMBRE, 75002 PARIS I0 00000
Cahill Colin director 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Frederic H Moll director C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Larkin C Raymond Jr director C/O MALLINCKRODT INC, 7733 FORSYTH BLVD, ST LOUIS MO 63105